Is Verrica Pharmaceuticals Inc (VRCA) overvalued? · rev $10.9M
Verrica Pharmaceuticals Inc (VRCA) is a biotechnology company listed on US.
This page asks whether Verrica Pharmaceuticals Inc (VRCA) looks expensive on cached numbers — not a short thesis.
Latest reported VRCA revenue for 2026-06-30 was $10.9M. Net income was -$22.8M. VRCA currently screens at market cap $79.7M.
VRCA currently screens at market cap $79.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VRCA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VRCA stock page for the full model, not this heading.
Not investment advice.